Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.
Soverini
Simona
S
Martinelli
Giovanni
G
Colarossi
Sabrina
S
Gnani
Alessandra
A
Castagnetti
Fausto
F
Rosti
Gianantonio
G
Bosi
Costanza
C
Paolini
Stefania
S
Rondoni
Michela
M
Piccaluga
Pier Paolo
PP
Palandri
Francesca
F
Giannoulia
Panagiota
P
Marzocchi
Giulia
G
Luatti
Simona
S
Testoni
Nicoletta
N
Iacobucci
Ilaria
I
Cilloni
Daniela
D
Saglio
Giuseppe
G
Baccarani
Michele
M
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001752:Blast Crisis / Q000188:drug therapy / Q000235:genetics; D017322:Clinical Trials, Phase II as Topic; D000069439:Dasatinib; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D005260:Female; D016313:Genes, abl; D006801:Humans; D007930:Leucine; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D010649:Phenylalanine; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000235:genetics; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*; D017211:Treatment Failure
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D010649:Phenylalanine; D007930:Leucine; D000069439:Dasatinib